Efficacy

Efficacy of Xpovio (Selinexor) in Treating Multiple Myeloma

Xpovio (selinexor) is a prescription medicine that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma in adult patients. Selinexor works as a selective inhibitor of nuclear export, targeting a protein called XPO1. This action leads to the accumulation of tumor suppressor proteins in the cell nucleus, thereby restoring their ability to halt cancer growth. The efficacy of Xpovio in combination with dexamethasone was demonstrated in a clinical trial involving patients with relapsed or refractory multiple myeloma who had received at least four prior therapies and whose disease was resistant to multiple other treatments.

In the pivotal STORM study, the combination of Xpovio and dexamethasone resulted in an overall response rate (ORR) of 25.3% in heavily pretreated patients. The median duration of response (DOR) was found to be 3.8 months. While these results show that Xpovio can be effective in treating multiple myeloma, especially in later lines of therapy, it is important to note that the response rates may vary and the treatment is associated with a range of side effects that need to be managed clinically.

Efficacy of Talquetamab (Talvey) in Treating Multiple Myeloma

Talquetamab (Talvey) is an investigational bispecific antibody that targets both GPRC5D, a novel multiple myeloma-specific antigen, and CD3 on T cells. By engaging both these proteins, talquetamab is designed to direct the body's immune system, specifically T cells, to kill multiple myeloma cells. As of the knowledge cutoff date, talquetamab is not yet approved by regulatory agencies but has shown promise in early clinical trials for the treatment of relapsed or refractory multiple myeloma.

In a phase 1 study, talquetamab demonstrated encouraging efficacy in patients with heavily pretreated multiple myeloma. Preliminary results indicated that talquetamab had an ORR of approximately 70% at the recommended phase 2 dose in patients who had received a median of six prior lines of therapy. These results suggest that talquetamab could become a valuable treatment option for patients with multiple myeloma, particularly those who have exhausted other therapies. However, further studies are required to fully establish its efficacy and safety profile.